Novo Shares Slump As CagriSema Misses 25% Weight Loss Target

The keenly awaited REDEFINE 1 study of Novo Nordisk’s combination anti-obesity agent has disappointed, despite it providing nearly 23% weight loss over the 68-week study. The data leave the company in a less competitive position than hoped in the fast-changing obesity market.